Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

Merck and Antengene joined forces to test ATG-022 with KEYTRUDA®, a combo that could strengthen Merck’s cancer-fighting ...

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller ...